Finland· FI-REL-REL46876
KANUMA
A sebelipase alfa product containing sebelipase alfa, registered in Finland by Alexion Europe SAS. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Sebelipase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB14 (sebelipase alfa), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Sebelipase alfa · ATC A16AB14
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Sebelipase Alfa
- Manufacturer
- Alexion Europe SAS
- Country
- Finland (FI)
- ATC code
- A16AB14
- ATC class
- Sebelipase alfa
- Defined daily dose
- 5 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sebelipase alfa in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKanuma 2 mg/mlAlexion Europe
- SwitzerlandKanuma 2 mg/ml, Konzentrat zur Herstellung einer InfusionslösungAlexion Pharma GmbH
- CzechiaKANUMAAlexion Europe SAS, Levallois-Perret
- IrelandKANUMA 2 mg/ml concentrate for solution for infusionAlexion Europe SAS
- IcelandKanumaAlexion Europe SAS
- NorwayKanumaAlexion Europe SAS (2)
- SwedenKanuma 2 mg/ml Koncentrat till infusionsvätska, lösningAlexion Europe SAS
- United StatesKANUMAAlexion Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kanuma
- Liechtenstein · Kanuma
- Norway · Kanuma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5b1f4cd3-08c7-4c23-ac08-8e3b32d10bc1 GET /v1/drugs/5b1f4cd3-08c7-4c23-ac08-8e3b32d10bc1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "5",
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": "mg",
"strength": "2 mg/ml",
"atc_label": "sebelipaasi alfa",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/15/1033/001",
"fimea_rel_id": "REL46876",
"authorised_at": "2015-08-28"
}See everything about sebelipase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.